Bone Mineral Density in Residents of Care Facilities for the Aged and Effect of Pharmacotherapy

Overview

Journal Yonago Acta Med

Specialty General Medicine

Date 2014 Jul 29

PMID 25067877

Authors

Takahiro Tokuda

Junichi Hasegawa

Akiko Matsuda

Hiroshi Hagino

Affiliations

Soon will be listed here.

Abstract

Background: Bone mineral densitometry has been proven to be a powerful tool for the diagnosis and treatment of osteoporosis, which is increasing with aging of the population, but opportunities to perform bone mineral densitometry in elderly facility residents, who are at a high risk of fracture, are scarce.

Methods: We measured the bone mineral density in 315 residents of 5 care facilities for the aged in middle Tottori Prefecture from 2002 to 2006. We also evaluated residents of an elderly nursing home with a history of fragility fracture and those with osteoporosis who were administered risedronate for its therapeutic effect.

Results: The bone mineral density was less than 70% of the young adult mean in 161 (51.1%) of the 315 subjects (aged 83.1 ± 7.8 years), 149 (57.8%) of the 258 women (83.9 ± 7.2 years), and 12 (21.1%) of the 57 men (79.8 ± 9.3 years). In the 13 subjects who were administered risedronate, the bone mineral density increased from 65.8 to 67.2% of the young adult mean from before to after the beginning of administration, but it decreased in the control group (n = 9). In those administered risedronate, the urinary level of N-telopeptide (a marker for bone resorption) began to decrease 3 months after the beginning of the administration and showed a significant decrease after 11 months (n = 8) compared with the control group. The mean pain score based on the visual analogue scale showed significant reduction in the risedronate group compared with the control group.

Conclusion: The bone mineral density was low in the facility residents and was less than 70% of the young adult mean in 57.8% of women and in 21.1% of men, more frequently than expected. Bone resorption and osteoporotic pain were suppressed by risedronate in osteopenic patients in such care facility.

References

Orimo H, Hayashi Y, Fukunaga M, Sone T, Fujiwara S, Shiraki M . Diagnostic criteria for primary osteoporosis: year 2000 revision. J Bone Miner Metab. 2001; 19(6):331-7. DOI: 10.1007/s007740170001. View

Masugata H, Senda S, Inukai M, Murao K, Hosomi N, Iwado Y . Association between bone mineral density and arterial stiffness in hypertensive patients. Tohoku J Exp Med. 2011; 223(2):85-90. DOI: 10.1620/tjem.223.85. View

Jorde R, Sundsfjord J, Haug E, Bonaa K . Relation between low calcium intake, parathyroid hormone, and blood pressure. Hypertension. 2000; 35(5):1154-9. DOI: 10.1161/01.hyp.35.5.1154. View

Sato Y, Iwamoto J, Kanoko T, Satoh K . Risedronate sodium therapy for prevention of hip fracture in men 65 years or older after stroke. Arch Intern Med. 2005; 165(15):1743-8. DOI: 10.1001/archinte.165.15.1743. View

Penning-van Beest F, Erkens J, Olson M, Herings R . Loss of treatment benefit due to low compliance with bisphosphonate therapy. Osteoporos Int. 2007; 19(4):511-7. PMC: 2267483. DOI: 10.1007/s00198-007-0466-1. View

Okochi J . Increase of mild disability in Japanese elders: a seven year follow-up cohort study. BMC Public Health. 2005; 5:55. PMC: 1175092. DOI: 10.1186/1471-2458-5-55. View

Osaki M, Tatsuki K, Hashikawa T, Norimatsu T, Chiba K, Motokawa S . Beneficial effect of risedronate for preventing recurrent hip fracture in the elderly Japanese women. Osteoporos Int. 2011; 23(2):695-703. PMC: 3261386. DOI: 10.1007/s00198-011-1556-7. View

Sato Y, Iwamoto J, Honda Y . RETRACTED: Beneficial effect of etidronate therapy in chronically hospitalized, disabled patients with stroke. J Stroke Cerebrovasc Dis. 2010; 19(3):198-203. DOI: 10.1016/j.jstrokecerebrovasdis.2009.04.006. View

Kushida K, Fukunaga M, Kishimoto H, Shiraki M, Itabashi A, Inoue T . A comparison of incidences of vertebral fracture in Japanese patients with involutional osteoporosis treated with risedronate and etidronate: a randomized, double-masked trial. J Bone Miner Metab. 2004; 22(5):469-78. DOI: 10.1007/s00774-004-0509-z. View

10.

Cappuccio F, Meilahn E, Zmuda J, Cauley J . High blood pressure and bone-mineral loss in elderly white women: a prospective study. Study of Osteoporotic Fractures Research Group. Lancet. 1999; 354(9183):971-5. DOI: 10.1016/s0140-6736(99)01437-3. View

11.

Huskisson E . Measurement of pain. Lancet. 1974; 2(7889):1127-31. DOI: 10.1016/s0140-6736(74)90884-8. View

12.

Ding H, Koinuma N, Stevenson M, Ito M, Monma Y . The cost-effectiveness of risedronate treatment in Japanese women with osteoporosis. J Bone Miner Metab. 2007; 26(1):34-41. DOI: 10.1007/s00774-007-0794-4. View

13.

Eastell R, Barton I, Hannon R, Chines A, Garnero P, Delmas P . Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res. 2003; 18(6):1051-6. DOI: 10.1359/jbmr.2003.18.6.1051. View

14.

Jinbayashi H, Aoyagi K, Ross P, Ito M, Shindo H, Takemoto T . Prevalence of vertebral deformity and its associations with physical impairment among Japanese women: The Hizen-Oshima Study. Osteoporos Int. 2002; 13(9):723-30. DOI: 10.1007/s001980200099. View

15.

Gupta G, Aronow W . Underuse of procedures for diagnosing osteoporosis and of therapies for osteoporosis in older nursing home residents. J Am Med Dir Assoc. 2003; 4(4):200-2. DOI: 10.1097/01.JAM.0000073963.49915.FC. View

16.

Cummings S, Kelsey J, Nevitt M, ODowd K . Epidemiology of osteoporosis and osteoporotic fractures. Epidemiol Rev. 1985; 7:178-208. DOI: 10.1093/oxfordjournals.epirev.a036281. View

17.

Oka H, Yoshimura N, Kinoshita H, Saiga A, Kawaguchi H, Nakamura K . Decreased activities of daily living and associations with bone loss among aged residents in a rural Japanese community: the Miyama Study. J Bone Miner Metab. 2006; 24(4):307-13. DOI: 10.1007/s00774-006-0688-x. View

18.

Orimo H, Nakamura T, Hosoi T, Iki M, Uenishi K, Endo N . Japanese 2011 guidelines for prevention and treatment of osteoporosis--executive summary. Arch Osteoporos. 2012; 7:3-20. PMC: 3517709. DOI: 10.1007/s11657-012-0109-9. View

19.

Tsuda K, Nishio I, Masuyama Y . Bone mineral density in women with essential hypertension. Am J Hypertens. 2001; 14(7 Pt 1):704-7. DOI: 10.1016/s0895-7061(01)01303-6. View

20.

Aspray T, Stevenson P, Abdy S, Rawlings D, Holland T, Francis R . Low bone mineral density measurements in care home residents--a treatable cause of fractures. Age Ageing. 2005; 35(1):37-41. DOI: 10.1093/ageing/afj018. View